Gene Therapy for Hemophilia: Progress and Setbacks

As the FDA delayed the approval of the world’s first gene therapy for hemophilia A, companies forged ahead with phase III trials to gather longer-term patient data.  On December 23, 2019, California-based BioMarin Pharmaceutical announced...

Online Exclusives

Emmanuelle Charpentier and Jennifer Doudna Awarded Nobel Prize for CRISPR

The 2020 Nobel Prize in Chemistry was awarded to microbiologist Emmanuelle Charpentier, PhD, and biochemist Jennifer A. Doudna, PhD, for their 2012 discovery of...

California Governor Passes Legislation for State-Sponsored Generic Drugs

California Governor Gavin Newsom recently signed bill SB 852, allowing the creation of a state-sponsored generic drug label, Cal-Rx, through which the state can...

News

From the Blood Journals

WIB_icon

Sequential Pembrolizumab and Chemotherapy Results in Excellent Responses in Newly Diagnosed...

A brief course of pembrolizumab monotherapy followed by AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) was associated with reductions in metabolic tumor volume and prolonged...
WIB_icon

Is Post-Discharge VTE Prophylaxis Necessary for Patients With COVID-19?

In hospitalized patients with COVID-19, the risk of venous thromboembolism (VTE) following discharge was not significantly greater compared with the VTE risk in patients...

Multimedia

Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström...

John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III...

Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma

Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma

Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...

On Location

On location

Investigating Tyrosine Kinase Inhibitors for ITP

In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators...
On location

ADAMTS13 Activity Levels Predict iTTP Recurrence

A study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress...
On location

Studies Confirm Long-Term Benefit of Gene Therapy for Hemophilia A

In two studies presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual...
On location

Is It Time for a Paradigm Shift for CAPS Treatment?

Newer treatment approaches that incorporate monoclonal antibodies reduce the mortality risk in patients with catastrophic...
On location

Late-Breaking Abstracts Address Thrombosis and COVID-19

A growing body of clinical evidence indicates that COVID-19 infection predisposes patients to arterial and...
On location

Extended Half-Life Factor VIII Fusion Protein Effective in Previously Untreated Hemophilia A

The use of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) appeared to be...

Latest Headlines

Advertisement

ASH Directions

ASH Directions

Diversity, Equity, and Inclusion in Hematology, and more

Diversity, Equity, and Inclusion in Hematology ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and...
ASH Directions

ASH Publishes New Clinical Practice Guidelines on AML in Older Adults, and more

ASH Publishes New Clinical Practice Guidelines on AML in Older Adults The American Society of Hematology (ASH) is pleased to announce the release of...

Sign up for our
eNewsletter!

The Society Pages

NCI Partners with Cancer Research UK, JADPRO Appoints Beth Faiman as Editor-in-Chief, and more

Fred Hutchinson Researchers Receive $3.5-Million Grant for Inherited Blood Disorder Treatment Hans-Peter Kiem, MD, PhD, and Roland Walter, MD, PhD, from the Fred Hutchinson Cancer...
The Society Pages

Remembering Edward Henderson, MD, and more

Remembering Edward Henderson, MD (1932 – 2020) Hematologist Edward Henderson, MD, passed away on June 25, 2020, at the age of 87.Dr. Henderson spent 12...
The Society Pages

Charles L. Sawyers Elected AACR President, Young Investigators Receive More Than $1 Million From...

Charles L. Sawyers Elected 2020-21 AACR President The Fellows of the American Association for Cancer Research (AACR) announced Charles L. Sawyers, MD, as the AACR...

Gene Therapy for Hemophilia: Progress and Setbacks

As the FDA delayed the approval of the world’s first gene therapy for hemophilia A, companies forged ahead with phase III trials to gather...

New Rules of the Road in TTP Management

In July 2020, the International Society on Thrombosis and Haemostasis (ISTH) issued its first-ever guidelines for the treatment of thrombotic thrombocytopenic purpura (TTP), helping...

Racism Persists in Medicine, Including Hematology

Medicine is not exempt from the explicit and implicit racism seen in other parts of American life. When Deirdra Terrell, PhD, MPH, started attending...